Unity Biotechnology — Technical Presentation (March 2025)
24 slides from Unity Biotechnology's technical presentation, Mar 24, 2025
Slide 1: UBX1325 Phase 2B ASPIRE Study 24- and 36-Week Data in DME
UNIT Y BIOTECHNOLOGY UBX1325 Phase 2B ASPIRE Study 24- and 36-Week Data in DME Robert Bhisitkul, M.D., Ph.D. Professor of Ophthalmology, UCSF Anirvan Ghosh, CEO Federico Grossi, CMO Lynne Sullivan, CFO Alicia Tozier, Chief Strategy Officer March 24, 2025
Slide 2: Special Note Regarding Forward-Looking Statements
Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc’s (“UNITY’s") understanding of cellular senescence and the role it plays in refinal diseases and disease
Slide 3: ASPIRE Ph2B Study in DME: Topline Results
ASPIRE Ph2B Study in DME: Topline Results ASPIRE Study Data Highlights + Patients on UBX1325 gained 5.2 letters at week 24 and 5.5 letters at week 36 - UBX1325 was Non-Inferior to Aflibercept at 9 out of 10 time points through 36 weeks (did not meet non-inferiority analysis at average of weeks 20 an
Slide 4: Senolytic Therapeutic Hypothesis and Mechanism of Action
UNITY BIOTECHNOLOGY Senolytic Therapeli Hypothesis Mechanism of Action
Slide 5: UNITY is Developing Senolytic Medicines to Eliminate Senescent Cells to Restore Vascular Health and Improve Vision
UNITY is Developing Senolytic Medicines to Eliminate Senescent Cells to Restore Vascular Health and Improve Vision Bre eakdon® Pepa Disease State Repaired State (intended results) Increased senescence burden Senescent cells removed Elevated inflammatory markers Resolution of inflammation Loss of vas
Slide 6: Ph2B ASPIRE Study in DME: 24- and 36-Week Results Following Treatment with UBX1325
UNITY BIOTECHNOLOGY 3 Ph2B ASPIRE Study in DME Me Patients 24- and 36-week Results Following Treatment with UBX1325
Slide 7: ASPIRE: DME Phase 2b Study Design (Head-to-head against aflibercept)
aspire ASPIRE: DME Phase 2b Study Design (Head-to-head against aflibercept) 24.Week Safety & 36-Week Safety & Efficacy Data Efficacy Data 4-5 weaks UBX1325 10 [lg IVT Es / Weeks 0 4 a 2 16 20 2 2B 2 36 = Aflibercept injection Patient Population: Participants with NPDR who have active DME despite tre
Slide 8: Patient Baseline Characteristics
Patient Baseline Characteristics Parameter, Units (SD) Aflibercept 2 mg (N=26) UBX1325 10 pg (N=26) Age, Years 65.9 (8.73) 66.2 (7.57) HBA1c, % 7.5 (1.50) 7.9 (1.87) Diabetes Dx, Years 14.4 (12.17) 21.4 (13.35) DME Dx, Years 3.4 (2.93) 4.7 (3.36) BCVA, ETDRS letters 63.3 (8.75) 61.6 (7.24) CST, um 4
Slide 9: BCVA Change from baseline through week 36 (excluding data post-rescue)
BCVA Change from baseline through week 36* (excluding data post-rescue) ~@ UBX1325 @ Aflibercept LS Mean Change From Baseline BCVA (ETDRS Letters) + SE ASPIRE (UBX1325-04) Se 0 4 8 12 16 20 24 28 32 36 Weeks *Data from all subjects through week 24 and majority of subjects through week 36 UNITY
Slide 10: BCVA Change from baseline through week 36 (including post-rescue data)
BCVA Change from baseline through week 36* (including post-rescue data) ° J uw ~@ UBX1325 @ Aflibercept ° LS Mean Change From Baseline BCVA (ETDRS Letters) + SE ASPIRE (UBX1325-04) 8A T 0 4 8 12 16 20 24 28 32 36 Weeks *Data from all subjects through week 24 and majority of subjects through week 36
Slide 11: UBX1325 was Non-Inferior to Aflibercept across Multiple Analyses
UBX1325 was Non-Inferior to Aflibercept across Multiple Analyses UBX1325 Aflibercept Confidence Interval (NI -4.5) At 24 weeks (excl. post-rescue data) | | 48 >90% Avg of weeks 20 and 24 (excl. post-rescue 3.6 i. ~88% data) At 24 weeks (incl. post-rescue data) iv] 48 >90% Avg of 20 and 24 weeks (inc
Slide 12: BCVA Changes in CST<400 um (at Baseline) Group
BCVA Changes in CST<400 um (at Baseline) Group* 15 au ga 10 ag eS fas zen 32 © UBX1325 5 ra} 0 =) Aflibercept: ou Bs igs a % a ASPIRE RISO excluding post-rescue data 1 0 T T T T T T T T T T T T T T T T T T T 0 4 8 12. 16 20 24 28 32 36 Weeks *Data from all subjects through week 24 and majority of su
Slide 13: BCVA Changes in CST<400 um (at Baseline) Group
BCVA Changes in CST<400 um (at Baseline) Group* 15 10 +4 = 048° LS Mean Change From Baseline BCVA (ETDRS Letters) + SE ASPIRE (UBX1325-04) a a 0 4 8 12, 16 20 24 28 32 36 *Data from all subjects through week 24 and majority of subjects through week 36 Pre-specified analysis, 60% of study population
Slide 14: BCVA Changes in CST<400 um (at Run-in) Group
BCVA Changes in CST<400 tm (at Run-in) Group* ) Aflibercept LS Mean Change From Baseline BCVA (ETDRS Letters) + SE ASPIRE (UBX1325-04) 10 14 0 4 8 12 16 20 24 28 32 36 Weeks *Data from all subjects through week 24 and majority of subjects through week 36 Pre-specified analysis UNITY
Slide 15: BCVA Changes in CST<400 um (at Run-in) Group
BCVA Changes in CST<400 tm (at Run-in) Group* Am -& UBX1325 ) Aflibercept LS Mean Change From Baseline BCVA (ETDRS Letters) + SE ASPIRE (UBX1325-04) 8 +4 0 4 8 12. 16 20 24 28 32 36 Weeks *Data from all subjects through week 24 and majority of subjects through week 36 Pre-specified analysis UNITY
Slide 16: CST Changes and Supplemental Anti-VEGF
UNITY BIOTECHNOLOGY CST Changes and Supplemental Anti-VEGF me
Slide 17: CST Change from baseline through week 36 (including data post-rescue)
CST Change from baseline through week 36* (including data post-rescue) @ Aflibercept ~@- UBX1325 LS Mean Change From Baseline CST (um) + SE ASPIRE (UBX1325-04) -100 S11 1111 T 0 4 8 12 16 20 24 28 32 36 Weeks *Data from all subjects through week 24 and majority of subjects through week 36 UNITY
Slide 18: Patients who Switched from Prior Aflibercept to UBX1325 had Stable CST
Patients who Switched from Prior Aflibercept to UBX1325 had Stable CST* 2204 Overall CST Increase Driven by severe patients, previously on faricimab 1704 e 1204 prior Anti-VEGF AFLIBERCEPT prior Anti-VEGF BEVACIZUMAB| © prior Anti-VEGF FARICIMAB Switched from Aflibercept to UBX1325 -majority of pati
Slide 19: Safety and AE Summary
Safety and AE Summary Parameter UBX1325 10 (N = 26) Subjects with at least one TEAE 43 (50.0) 19 (73.1) Non-Ocular TEAE 9 (34.6) 9 (34.6) Grade >=3 TEAE 3 (11.5) 5 (19.2) Serious TEAE 2(7.7) 5 (19.2) Ocular TEAE for Study Eye 10 (38.5) 17 (65.4) Treatment-related Ocular TEAE for Study Eye T (26.9) 8
Slide 20: ASPIRE Ph2B Study in DME: Key Insights
ASPIRE Ph2B Study in DME: Key Insights ASPIRE Study Data Highlights + Patients on UBX1325 gained over 5 letters of vision through 36 weeks in a difficult to treat patient population + UBX1325 generally outperformed Aflibercept in subjects who had less aggressive disease (baseline CST < 400 um) * Pat
Slide 21: Unmet Need in DME and Current Treatment Paradigm
UNITY BIOTECHNOLOGY = fa =) = RD) a ~~ ; \ Unmet Need in DME and” ~— Current Treatment Paradigm
Slide 22: Unmet Needs Exist for Patients with Diabetic Macular Edema
Unmet Needs Exist for Patients with Diabetic Macular Edema 35.5 MANDO poopie win ome worwide DME: Markatonearuntey $9.6b global DME market by 2031! a $ 4.8 billion 50%* iscontinue freatment 6 months? High treatment burden with chronic anti-VEGF 58% 1.7 million isteus Non i Frequent . Reni lL n Dosin
Slide 23: A Targeted Offering Designed to Address Patient Unmet Needs
A Targeted Offering Designed to Address Patient Unmet Needs Focus UBX1325 efforts on the sub-optimal responder segment, while expanding to the declining vision patient segment Current DME Treatment Paradigm & Key Patient Segments Tx Experienced Patients (Diabetic Macular Edema) Suboptimal Vision [re
Slide 24: UNITY Biotechnology
UNITY BIOTECHNOLOGY
Unity Biotechnology — Technical Presentation (March 2025) on 6ix